32 minutes ago
Topline results from APPULSE-PNH show the positive efficacy and safety of twice-daily oral iptacopan in adults with PNH switched from anti-C5 therapies.
1 hour ago
Andreas Kremer, MD, PhD, MHBA, explains seladelpar’s impact on pruritus in PBC based on findings from a posthoc analysis of the RESPONSE trial.
1 hour ago
Andreas Kremer, MD, PhD, MHBA, reviews emerging therapies in PBC, focusing specifically on seladelpar and its impact on pruritus.
1 hour ago
Andreas Kremer, MD, PhD, MHBA, explains shortcomings of traditional PBC therapies for addressing pruritus and what advantages newer agents may offer.
1 hour ago
Andreas Kremer, MD, PhD, MHBA, describes the burden of pruritus in PBC and the toll it can take on patients’ quality of life.